Homburger advised Santhera in connection with its CHF 20 m Royalty Monetization and Convertible Bond Financing

On September 23, 2025, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had secured an USD 13 m royalty monetization financing with R-Bridge, an affiliate of CBC Group, Asia’s largest healthcare-focused investment firm. Santhera is monetizing 25% of net royalties on its product AGAMREE^®. In addition, Santhera has agreed with Highbridge Capital Management, LLC on an additional CHF 10 m of funding and the exchange of the existing CHF 7 m private convertible bond for a new convertible bond.

Homburger advises Santhera on the transaction. The Homburger team is led by Daniel Häusermann (Corporate / M&A, Capital Markets) and includes Stefan Oesterhelt (Tax), Eduard De Zordi and Daniel Hulmann (both Financing, Investment Products, Capital Markets) as well as Daniel Bötticher (Corporate / M&A). Ropes & Gray acts as U.S. counsel to Santhera.